Asthma
Conditions
Interventions
Study Group:Montelukast sodium mouth solvent film
Sponsors
Beijing Children's Hospital, Capital University of Medical Sciences
Eligibility
Sex/Gender
All
Age
3 Years to 14 Years
Inclusion criteria
Inclusion criteria: 1. Age 3-14 years (inclusive) , regardless of gender; 2. Asthma diagnosed by a doctor or previous diagnosis 3. Children with asthma who had not been treated with high-dose ICS for nearly 1 month; 4. The subjects were in accordance with the long-term treatment plan of our country, and had to choose 3-4 grades, and had to adopt the combination therapy of middle-low dose ICS and LTRA (montelukast sodium) . 5. 2024 from 1 April to 31 October. 6. The informed consent process conforms to the provisions, and the written informed consent signed by the legal guardian.
Exclusion criteria
Exclusion criteria: 1. Severe liver failure 2. Patients who had been treated with mcab or Hapten therapy for the last 3 months. 3. High-dose ICS was used for initial control of asthma; 4. Adenoid hypertrophy, sinusitis, moderate to severe allergic rhinitis; 5. Previous diagnoses of chronic psychiatric or other systemic conditions such as tic disorder or tic disorder. 6. Previous adverse reactions to Leukotriene antagonist; 7. High doses of ICS or glucocorticoid have been used in the last month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TRACK/C-ACT/ACT; | — |
Secondary
| Measure | Time frame |
|---|---|
| Palatability;Compliance; Assessment of asthma control;Lung function;Eosinophil granulocyte count;Security; | — |
Countries
China
Contacts
Public ContactLi Xiang/Xiaoling Wang
Beijing Children's Hospital, Capital University of Medical Sciences
Outcome results
None listed